Galcanezumab + Placebo

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Episodic Cluster Headache

Conditions

Episodic Cluster Headache

Trial Timeline

May 22, 2015 → Jun 4, 2018

NCT ID

NCT02397473

About Galcanezumab + Placebo

Galcanezumab + Placebo is a phase 3 stage product being developed by Eli Lilly for Episodic Cluster Headache. The current trial status is completed. This product is registered under clinical trial identifier NCT02397473. Target conditions include Episodic Cluster Headache.

What happened to similar drugs?

3 of 15 similar drugs in Episodic Cluster Headache were approved

Approved (3) Terminated (1) Active (11)

✅Atogepant + UbrogepantAbbVieApproved

✅AMG334 + Oral ProphylacticNovartisApproved

✅MethylprednisoloneBrain BiotechApproved

🔄DFN-11Dr. Reddy's LaboratoriesPhase 3

🔄GalcanezumabEli LillyPhase 3

🔄Galcanezumab + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04616326	Phase 3	Active	Nov 25, 2020	Mar 1, 2027	Chronic Migraine
NCT04085289	Phase 1	Completed	Nov 20, 2019	May 21, 2020	Healthy
NCT03963232	Phase 3	Completed	Jul 30, 2019	Mar 11, 2022	Episodic Migraine
NCT03559257	Phase 3	Completed	Jul 31, 2018	Sep 19, 2019	Migraine
NCT03432286	Phase 3	Active	Mar 14, 2018	Nov 1, 2026	Episodic Migraine
NCT02959177	Phase 2	Completed	Nov 9, 2016	Jan 18, 2019	Migraine
NCT02614196	Phase 3	Completed	Dec 4, 2015	Oct 5, 2018	Migraine
NCT02614261	Phase 3	Completed	Nov 30, 2015	Jul 14, 2021	Chronic Migraine
NCT02614183	Phase 3	Completed	Nov 30, 2015	Aug 9, 2018	Migraine
NCT02576951	Phase 1	Completed	Oct 19, 2015	Jan 8, 2018	Healthy
NCT02397473	Phase 3	Completed	May 22, 2015	Jun 4, 2018	Episodic Cluster Headache
NCT02163993	Phase 2	Completed	Jul 7, 2014	Feb 12, 2018	Migraine Headache

Competing Products

19 competing products in Episodic Cluster Headache

See all competitors

Product	Company	Stage	Hype Score
DFN-11	Dr. Reddy's Laboratories	Phase 3	37
Galcanezumab	Eli Lilly	Phase 3	40
Galcanezumab + Placebo	Eli Lilly	Phase 3	44
Galcanezumab + Placebo	Eli Lilly	Phase 3	40
BOTOX + Placebo	AbbVie	Phase 3	32
Atogepant 60 mg	AbbVie	Phase 3	40
Atogepant + Ubrogepant	AbbVie	Approved	43
Atogepant + Placebo-Matching Atogepant	AbbVie	Phase 3	47
SOM230 + Placebo	Novartis	Phase 2	27
AMG334 + Oral Prophylactic	Novartis	Approved	43
AMG334 (70 mg) Pre-Filled Syringe (PFS) + Placebo Pre-Filled Syringe (PFS)	Novartis	Phase 3	40
Erenumab	Novartis	Phase 3	40
Placebo + AMG 301	Amgen	Phase 2	35
Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride)	Pfizer	Phase 1	29
Eptinezumab + Placebo	Lundbeck	Phase 3	44
Eptinezumab + Placebo	Lundbeck	Phase 3	37
Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A	Ipsen	Phase 3	41
IPN10200 + IPN10200 dose A + IPN10200 dose B	Ipsen	Phase 2	39
Methylprednisolone	Brain Biotech	Approved	33